Citi analyst Joanne Wuensch lowered the firm’s price target on Tandem Diabetes (TNDM) to $50 from $57 and keeps a Buy rating on the shares as part of a 2025 outlook for the U.S. medical technology sector. The stocks that outperformed in 2024 followed the traditional med tech path, and Citi expects the same in 2025: launching differentiated products that can be leveraged to the bottom-line, with management teams providing consistent delivery, the analyst tells investors in a research note. Citi names Boston Scientific (BSX) and Insulet (PODD) its top picks for 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Morgan Stanley upgrades ‘too cheap’ Tandem Diabetes to Overweight
- Tandem Diabetes upgraded to Overweight from Equal Weight at Morgan Stanley
- Tandem Diabetes price target raised to $60 from $58 at Barclays
- Tandem Diabetes price target lowered to $40 from $43 at UBS
- Tandem Diabetes price target lowered to $56 from $57 at Canaccord